Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, ...

At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At ...

BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at ...

Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED) -- -- ...

Transportation Secretary Sean Duffy testifies Wednesday to pitch the administration’s take on a transportation and ...

Nvidia Corporation's FY25 revenue surged 114% YoY, driven by AI dominance and Blackwell architecture. Click for my updated ...

Rep. Rob Wittman (R-Va.), vice chair of the House Armed Services Committee, said he wants to see more resources pushed ...

SINGAPORE and PRINCETON, N.J., March 27, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced topline data of a Phase 2b ...

Shares of Regulus Therapeutics (NASDAQ:RGLS) spiked on Thursday after the microRNA-focused drug developer announced ...

Abstracts and additional details can be found at the SIRS 2025 website.

The entire 36-week data for the remaining subjects in the trial is anticipated in the second quarter of this year.